Understanding the emergence of leukemia

January 25, 2019

Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children. This blood cancer appears from the precursor cells that produce T lymphocytes (a type of white blood cells). A new study from Instituto Gulbenkian de Ciencia (IGC), conducted in mice, shows that leukemia can emerge as a consequence of prolonging the presence of precursor cells in the thymus. This work was now published in the scientific journal The Journal of Immunology.

T lymphocytes are essential to fight infections and prevent cancer. They develop in the thymus, an organ located above the heart. Their development relies on the seeding by precursor cells that come from the bone marrow and enter the thymus to differentiate and learn to protect the organism. This is a process secured by an "assembly line" in the thymus in which many of the precursor cells enter, but are discarded if they malfunction. The work led by Vera Martins at the IGC shows that if there is a problem with the precursor cells that come from the bone marrow, the thymus alone can maintain its "assembly line" for some time. However, this function is associated with a high risk of developing T-cell acute lymphoblastic leukemia.

The IGC team tested several genetic factors in mice known to be involved in the formation of T lymphocytes. The results showed that in all conditions tested there was an incidence of ca. 80% of this type of leukemia. "Our study shows the importance of investigating in detail the cellular, genetic and physiological mechanisms associated with the process of normal cell differentiation, and opens the door to understand how leukemia can appear in cells that should be learning to defend our body," says Vera Martins.
-end-
This work was supported by Instituto Gulbenkian de Ciencia and by Fundacao para a Ciencia e a Tecnologia.

Instituto Gulbenkian de Ciencia

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.